Mingde Biology: Resumed trading on April 22nd and implemented delisting risk warning, abbreviated as *ST Mingde.

Mingde Biotechnology announcement, the company's stock was suspended on April 21 for one day, and resumed trading on April 22 with the implementation of a delisting risk warning. The stock symbol was changed from "Mingde Biotechnology" to "*ST Mingde", and the daily limit of price fluctuation is 5%. According to the company's 2025 annual report, the company's total profit for 2025 was a loss of 63.794 million yuan, the net profit attributable to the shareholders of the listed company was a loss of 16.4607 million yuan, and the net profit attributable to the shareholders of the listed company after deducting non-recurring gains and losses was a loss of 117 million yuan. The operating income was 265 million yuan, and the adjusted operating income was 241 million yuan. According to relevant regulations, if the financial indicators for the 2025 year touch the situation where "the total profit, net profit, and net profit after deducting non-recurring gains and losses audited in the most recent accounting year are all negative, and the adjusted operating income is less than 300 million yuan", the Shenzhen Stock Exchange will implement a risk warning for the company's stock trading. If the company experiences the above situation in the 2026 year, the Shenzhen Stock Exchange will decide to delist the company's stock.